ResMed Highlights its Picks for Top COPD Research of 2017
Today is World COPD Day and in recognition of that fact, ResMed, a global leader in COPD and respiratory care treatment, has selected its top five COPD research findings and therapy recommendations from the past year.
COPD (chronic obstructive pulmonary disease) plagues more than 380 million people globally and is the world’s fourth leading cause of death – only heart disease, stroke and lower respiratory tract infections account for more deaths, according to the World Health Organization.
Summaries of each research finding and recommendation are below:
1. Updated GOLD Report recommends home NIV for hypercapnic, recently hospitalized COPD patients (Vogelmeier CF et al. Am J Respir Crit Care Med 2017)
The latest GOLD report, a collection of peer-reviewed best-practice treatments by global COPD experts, offers a more proactive recommendation for the use of NIV (non-invasive ventilation) to reduce hospital readmissions, particularly for those with pronounced daytime persistent hypercapnia (increased levels of CO2 in their blood).
2. JAMA publishes landmark HOT-HMV study that finds NIV decreased risk of re-hospitalization or death by 51 percent (Murphy PB et al. JAMA 2017)
In the landmark HOT-HMV study published in JAMA, patients who used home NIV in addition to oxygen therapy had a 51 percent decreased risk of re-hospitalization or death, and stayed out of the hospital more than three times longer than those on oxygen alone.
3. PAP therapy may reduce COPD hospitalizations (Vasquez MM et al. Am J Med 2017)
In a retrospective analysis of more than 1.8 million COPD patients, only 7.5 percent were using CPAP (continuous positive airway pressure), bilevel, or NIV – and each of those therapies individually were associated with a lower hospitalization risk six months after treatment vs. six months before.
4. High prevalence of sleep-disordered breathing found in patients with COPD and mild hypoxemia (Silva JLR, et al. J Bras Pneumol 2017)
A Brazilian study of patients with COPD and mild hypoxemia (an abnormally low level of oxygen in the blood) found that 61 percent had sleep-disordered breathing: 21 percent had obstructive sleep apnea; 39 percent had isolated nocturnal hypoxemia. Researchers concluded that patients with COPD and mild hypoxemia “would benefit from sleep studies.”
5. Nasal high-flow therapy improves ventilation in COPD patients (Bräunlich J et al. Int J Chron Obstruct Pulmon Dis 2016)
Nasal high-flow (NHF) provides a warmed and humidified air stream up to 60 L/min. This interventional clinicial study of patients with severe COPD found that NHF enhances patients’ breathing effectiveness and reduces their pCO2 and the amount of work it takes them to breathe. Researchers concluded NHF should be evaluated as a new ventilator support device.
This blog post contains general information about medical conditions and treatments. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. The information is not advice, and should not be treated as such. You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
If you have any specific questions about any medical matter, you should consult your doctor or other professional healthcare provider. If you think you may be suffering from any medical condition, you should seek immediate medical attention. You should never delay seeking medical advice, disregard medical advice, or discontinue medical treatment because of information on this website. The views expressed on this blog and website have no relation to those of any academic, hospital, practice, or other institution with which the authors are affiliated and do not directly reflect the views of ResMed or any of its subsidiaries or affiliates.